Figure 2.
Overall survival according to group (dFLC <50 or ≥50 mg/L) and heart involvement. (A) Overall survival of patients with amyloid heart involvement. Median overall survival: 23.0 months (dFLC ≥50 mg/L) vs 92.0 months (dFLC <50 mg/L). (B) Overall survival of all patients according to Mayo 2004 stages. Median overall survival: 110.9 months (I) vs 58.0 months (II) vs 11.5 months (III). (C) Overall survival of patients with an initial dFLC ≥50 mg/L according to Mayo 2004 stages. Median overall survival: 97.5 months (I) vs 54.2 months (II) vs 11.7 months (III). (D) Overall survival of patients with an initial dFLC <50 mg/L according to Mayo 2004 stages. Median overall survival: not reached (I) vs 92.0 months (II) vs 6.9 months (III).

Overall survival according to group (dFLC <50 or ≥50 mg/L) and heart involvement. (A) Overall survival of patients with amyloid heart involvement. Median overall survival: 23.0 months (dFLC ≥50 mg/L) vs 92.0 months (dFLC <50 mg/L). (B) Overall survival of all patients according to Mayo 2004 stages. Median overall survival: 110.9 months (I) vs 58.0 months (II) vs 11.5 months (III). (C) Overall survival of patients with an initial dFLC ≥50 mg/L according to Mayo 2004 stages. Median overall survival: 97.5 months (I) vs 54.2 months (II) vs 11.7 months (III). (D) Overall survival of patients with an initial dFLC <50 mg/L according to Mayo 2004 stages. Median overall survival: not reached (I) vs 92.0 months (II) vs 6.9 months (III).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal